Literature DB >> 11709511

Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease.

E Louis1, A Collard, A F Oger, E Degroote, F A Aboul Nasr El Yafi, J Belaiche.   

Abstract

BACKGROUND: Crohn's disease is a heterogeneous disorder with both a genetic and environmental aetiology. Clinical classifications of the disease, such as the newly proposed Vienna classification, may help to define subgroups of patients suitable for studying the influence of specific genetic or environmental factors. AIM: To assess the stability over the course of the disease of its location and behaviour, as determined according to the Vienna classification. PATIENTS AND METHODS: The notes of 297 Crohn's disease patients regularly followed up at our institution were carefully reviewed retrospectively. The behaviour and location of the disease according to the Vienna classification were determined at diagnosis and after 1, 3, 5, 10, 15, 20, and 25 years of follow up. The proportions of the different behaviours and locations of the disease were calculated at these time points. A statistical analysis of the evolution of these characteristics over 10 years was performed on a subgroup of 125 patients with at least 10 years of follow up. The influence of age at diagnosis on location and behaviour of the disease was assessed as well as the influence of location on the behaviour of the disease.
RESULTS: The location of the disease remained relatively stable over the course of the disease. Although the proportion of patients who had a change in disease location became statistically significant after five years (p=0.01), over 10 years only 15.9% of patients had a change in location (p<0.001). We observed a more rapid and prominent change in disease behaviour, which was already statistically significant after one year (p=0.04). Over 10 years, 45.9% of patients had a change in disease behaviour (p<0.0001). The most prominent change was from non-stricturing non-penetrating disease to either stricturing (27.1%; p<0.0001) or penetrating (29.4%; p<0.0001) disease. Age at diagnosis had no influence on either location or behaviour of disease. Ileal Crohn's disease was more often stricturing, and colonic or ileocolonic Crohn's disease was more often penetrating: this was already the case at diagnosis and became more prominent after 10 years (p<0.05).
CONCLUSIONS: Location of Crohn's disease, as defined by the Vienna classification, is a relatively stable phenotype which seems suitable for phenotype-genotype analyses. Behaviour of Crohn's disease according to the Vienna classification varies dramatically over the course of the disease and cannot be used in phenotype-genotype analyses. The potential influence of genes on the behaviour of Crohn's disease should be studied in subgroups of patients defined by their disease behaviour after a fixed duration of disease.

Entities:  

Mesh:

Year:  2001        PMID: 11709511      PMCID: PMC1728556          DOI: 10.1136/gut.49.6.777

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

Review 1.  Inflammatory bowel disease: etiology and pathogenesis.

Authors:  C Fiocchi
Journal:  Gastroenterology       Date:  1998-07       Impact factor: 22.682

2.  HLA-DRB1*03, but not the TNFA -308 promoter gene polymorphism, confers protection against fistulising Crohn's disease.

Authors:  G Bouma; A C Poen; M A García-González; G M Schreuder; R J Felt-Bersma; S G Meuwissen; A S Pena
Journal:  Immunogenetics       Date:  1998-05       Impact factor: 2.846

3.  The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease.

Authors:  J Satsangi; C J Landers; K I Welsh; K Koss; S Targan; D P Jewell
Journal:  Inflamm Bowel Dis       Date:  1998-02       Impact factor: 5.325

4.  Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup.

Authors:  E A Vasiliauskas; S E Plevy; C J Landers; S W Binder; D M Ferguson; H Yang; J I Rotter; A Vidrich; S R Targan
Journal:  Gastroenterology       Date:  1996-06       Impact factor: 22.682

5.  Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics.

Authors:  M Peeters; H Nevens; F Baert; M Hiele; A M de Meyer; R Vlietinck; P Rutgeerts
Journal:  Gastroenterology       Date:  1996-09       Impact factor: 22.682

6.  Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms.

Authors:  A J Greenstein; P Lachman; D B Sachar; J Springhorn; T Heimann; H D Janowitz; A H Aufses
Journal:  Gut       Date:  1988-05       Impact factor: 23.059

7.  Crohn's disease: concordance for site and clinical type in affected family members--potential hereditary influences.

Authors:  T M Bayless; A Z Tokayer; J M Polito; S A Quaskey; E D Mellits; M L Harris
Journal:  Gastroenterology       Date:  1996-09       Impact factor: 22.682

8.  Clinical patterns of familial inflammatory bowel disease.

Authors:  J Satsangi; C Grootscholten; H Holt; D P Jewell
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

9.  Molecular evidence for two forms of Crohn disease.

Authors:  E C Gilberts; A J Greenstein; P Katsel; N Harpaz; R J Greenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

10.  TAP gene transporter polymorphism in inflammatory bowel diseases.

Authors:  D Heresbach; M Alizadeh; J F Bretagne; A Dabadie; J F Colombel; M Pagenault; N Heresbach-Le Berre; B Genetet; M Gosselin; G Semana
Journal:  Scand J Gastroenterol       Date:  1997-10       Impact factor: 2.423

View more
  222 in total

1.  Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes.

Authors:  Marla C. Dubinsky; Phillip P. Fleshner
Journal:  Curr Treat Options Gastroenterol       Date:  2003-06

2.  Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001.

Authors:  Laszlo Lakatos; Gabor Mester; Zsuzsanna Erdelyi; Mihaly Balogh; Istvan Szipocs; Gyorgy Kamaras; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

3.  Impact of smoking on disease phenotype and postoperative outcomes for Crohn's disease patients undergoing surgery.

Authors:  Myles R Joyce; Christine D Hannaway; Scott A Strong; Victor W Fazio; Ravi P Kiran
Journal:  Langenbecks Arch Surg       Date:  2011-10-22       Impact factor: 3.445

4.  The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn's disease independent of the IL23R genotype.

Authors:  Matthias Jürgens; Stephan Brand; Rüdiger P Laubender; Julia Seiderer; Jürgen Glas; Martin Wetzke; Johanna Wagner; Simone Pfennig; Cornelia Tillack; Florian Beigel; Maria Weidinger; Fabian Schnitzler; Martin E Kreis; Burkhard Göke; Peter Lohse; Karin Herrmann; Thomas Ochsenkühn
Journal:  J Gastroenterol       Date:  2010-04-29       Impact factor: 7.527

5.  Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics.

Authors:  Eun Soo Kim; Won Ho Kim
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

6.  Prediction of disease course in inflammatory bowel diseases.

Authors:  Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

Review 7.  Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn's disease--review of the literature.

Authors:  Andreas G Wibmer; Anton J Kroesen; Jörn Gröne; Heinz-Johannes Buhr; Joerg-Peter Ritz
Journal:  Int J Colorectal Dis       Date:  2010-07-14       Impact factor: 2.571

8.  Tailoring the treatment to the individual in Crohn's disease.

Authors:  Edouard Louis; Jacques Belaiche; Catherine Reenaers
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

9.  Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasome.

Authors:  Marjorie De la Fuente; Luigi Franchi; Daniela Araya; David Díaz-Jiménez; Mauricio Olivares; Manuel Álvarez-Lobos; Douglas Golenbock; María-Julieta González; Francisco López-Kostner; Rodrigo Quera; Gabriel Núñez; Roberto Vidal; Marcela A Hermoso
Journal:  Int J Med Microbiol       Date:  2014-02-06       Impact factor: 3.473

10.  What can we learn from inflammatory bowel disease in developing countries?

Authors:  Sunny H Wong; Siew C Ng
Journal:  Curr Gastroenterol Rep       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.